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Abstract  
Thyroid hormone (TH) receptors are present in the myocardium and vascular tissue, and 
minor alterations in TH concentration can affect cardiovascular (CV) physiology. The 
potential mechanisms that link CV disease with thyroid dysfunction are endothelial 
dysfunction, changes in blood pressure, myocardial systolic and diastolic dysfunction, and 
dyslipidemia. In addition, cardiac disease itself may lead to alterations in TH concentrations, 
notably low triiodothyronine (T3) syndrome, that are associated with higher morbidity and 
mortality. Experimental data and small clinical trials have suggested a beneficial role of TH 
in ameliorating CV disease. The aim of this review is to provide clinicians dealing with CV 
conditions with an overview of the current knowledge of TH perturbations in CV disease.  
 
Condensed Abstract: Both overt as well as subclinical thyroid disease are associated with 
cardiovascular diseases, including atrial fibrillation, heart failure, and coronary heart disease. 
In addition, a significant proportion of patients with heart failure and acute myocardial 
infarction have an isolated reduction in circulating triiodothyronine (T3) levels, a finding that 
is associated with worse prognosis. Small trials of thyroid hormone replacement therapy in 
various cardiovascular conditions have shown benefit, but large, adequately-powered trials 
assessing hard outcomes are required before efficacy and safety can be fully evaluated.  
 
Key words: acute myocardial infarction, amiodarone, heart failure, thyroxine, 
triiodothyronine  
 
Abbreviations and Acronyms: 
AF = atrial fibrillation 
AIT = amiodarone-induced thyrotoxicosis  
AMI = acute myocardial infarction 
CV = cardiovascular 
CHD = coronary heart disease 
D (1–3) = deiodinase enzymes (1–3) 
HF = heart failure  
LDL = low density lipoprotein 
MHC = myosin heavy chain 
PLB = phospholamban 
rT3 = reverse T3 
SCH = subclinical hypothyroidism 
SERCA = sarcoplasmic reticulum adenosine triphosphatase 
SHyper = subclinical hyperthyroidism 
SVR = systemic vascular resistance 
T3 = triiodothyronine 
T4 = thyroxine 
TH = thyroid hormones  
TR = thyroid hormone receptor 
TRH = thyrotropin releasing hormone 
TSH = thyrotropin 
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INTRODUCTION  
Despite major advances in their prevention and treatment, cardiovascular (CV) 
diseases remain the single largest cause of death globally (1). Recurrent ischemia resulting in 
adverse CV events following optimal treatment for an acute coronary syndrome occurs in 
approximately 10% of subjects in randomized controlled trials (RCTs) (2), and nearly double 
this in real-world registries (3). The inexorable progress of CV disease, despite optimal 
guideline-based primary and secondary prevention, suggests a multifactorial etiology and the 
need to assess other precipitants that may exacerbate existing CV disease.  
Thyroid hormone receptors (TRs) are present in both the myocardium and vascular 
endothelial tissues, thereby allowing changes in circulating thyroid hormone (TH) 
concentration to modulate end-organ activity. Patients who are overtly hypo- or hyperthyroid 
show CV and hematologic manifestations that are well-documented, and both can, if left 
untreated, accelerate the onset of symptomatic CV disease. However, the clinical significance 
of mild thyroid dysfunction (subclinical thyroid disease) is uncertain. Minor changes in TH 
concentration may have an adverse impact on the CV system, and subclinical thyroid 
dysfunction has been associated with a 20% to 80% increase in vascular morbidity and 
mortality risk (4–6). Observational studies report increased adverse CV biomarkers and 
myocardial strain, but, in the absence of mechanistic studies and large RCTs, no cause and 
effect has been proven. Nevertheless, thyroid disease, both overt and subclinical, is a global 
burden and associated with increased CV disease. The wide availability and affordability of 
treatments for correcting TH dysfunction has led to increased interest in exploring the role of 
TH in CV disease. This review summarizes the role of TH in CV function and diseases. 
MOLECULAR AND CELLULAR MECHANISMS OF TH ACTION 
PHYSIOLOGY OF THYROID FUNCTION. Thyroid function is regulated by the 
hypothalamic-pituitary-thyroid axis via a classic endocrine feedback loop mechanism. 
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Thyrotropin-releasing hormone (TRH) is secreted at the level of the hypothalamus and 
stimulates the anterior pituitary to produce thyroid-stimulating hormone (TSH), which, in 
turn, drives the thyroid gland to release TH. TH levels regulate TRH and TSH production and 
release (7). TSH has a log-linear relationship with thyroxine (T4) levels; therefore, even mild 
changes in TH concentrations lead to large changes in TSH. Thus, serum TSH is a robust 
marker of systemic TH status. The 2 main iodinated TH are T4 and triiodothyronine (T3). 
Both have biological effects; however, T3 is considered the active and more potent hormone. 
The normal negative feedback regulation of thyroid function is disrupted by illness, including 
conditions such as acute myocardial infarction (AMI) or heart failure (HF), and is 
characterized by a reduction in serum TH without a concomitant rise in circulating TSH 
levels (termed nonthyroidal illness and further discussed later). With the recognition that 
TSH is extremely sensitive to subtle changes in circulating TH concentrations, and with the 
advent of high-sensitivity TSH assays, clinicians are able to detect subtle changes in thyroid 
function, leading to the concept of subclinical thyroid disease.  
TH ACTION ON CARDIAC MYOCYTES. Genomic effects of TH are mediated by TH 
nuclear receptors located in the intracellular compartment. The protein receptors bind T3 with 
greater (>10×) affinity than T4 (8). In mammals, these receptor proteins exist in 2 isoforms, α 
and β (TRα and TRβ), and bind to TH response elements in the promoter regions of TH-
responsive genes. TRα and TRβ activate expression of positively regulated genes in the 
presence of T3 and repress expression in its absence. The TRα1 isoform has been shown to 
play an important role in the regulation of cardiac genes (Figure 1). A list of cardiac genes 
regulated by TH can be found in Table 1.  
The contractile apparatus of the cardiac myocyte contains the myosin heavy chains (MHCs), 
α and β (α-MHC and β-MHC). α-MHC, the fast myosin, and β-MHC, the slow myosin, are 
positively and negatively regulated by T3, respectively. Cardiac contractility is further 
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regulated by several important cardiac proteins, including the sarcoplasmic reticulum calcium 
adenosine triphosphatase (SERCA2) and its inhibiting counterpart phospholamban (PLB). 
SERCA2 functions to pump calcium ions (Ca2+) back into the sarcoplasmic reticulum in the 
relaxation phase of myofilament contraction. SERCA2 is positively regulated by T3, whereas 
PLB is negatively regulated. Together, they are responsible for the kinetics of calcium ion 
influx into (and subsequent efflux from) the sarcoplasmic reticulum. Efficient calcium 
sequestration and release is essential for energetically optimal cardiac myocyte relaxation and 
contraction. This lusitropic effect of TH is a characteristic of T3 regulation of myocyte 
contractility (9). Decreased calcium cycling in the cardiac myocyte has been reported in the 
impaired diastolic function of hypothyroidism, with aging in humans, and in experimental 
models of HF. Other important cardiac genes regulated by TH include those encoding the TR 
proteins themselves, the voltage-gated potassium ion (K+) channels (Kv1.5 and Kv4.2), and 
the sodium/calcium ion (Na+/Ca2+) exchanger (NCX1). 
In addition to the genomic effects of T3 described previously, TH (both T4 and T3), 
exert nongenomic effects on the cardiac myocyte and, as discussed later, on the vasculature. 
Nongenomic effects are usually receptor-independent, and largely occur at the plasma 
membrane, regulating ion transporter activity (10). Nongenomic mechanisms are identified 
by their rapid rate of action. Several ion channels that are transcriptionally regulated by TH 
are also post-translationally regulated by nongenomic mechanisms. These combined 
mechanisms at the level of the atrial myocyte are responsible, in part, for the ability of T3 to 
increase the heart rate. The other pathway mediating the chronotropic effect of thyrotoxicosis 
relates to the decrease in vagal tone and enhanced adrenergic tone characteristic of 
hyperthyroidism (11). 
Unlike steroid hormones, T3 is not lipid-soluble and must be transported into the 
cytoplasm of TH-responsive cells. Several families of TH transporters have been identified, 
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including the Na+-taurocholate cotransporting polypeptides, the Na+-independent organic 
anion transporting polypeptides, the heterodimeric L-type amino acid transporters, and, 
perhaps most importantly, the monocarboxylate transporters (MCTs) 8 and 10, which are 
highly specific for iodothyronines. MCT8 and 10 are expressed in the rodent heart, but it is 
unclear whether they have a role in the human heart. In humans, MCT8 mutations are the 
cause of Allan-Herndon-Dudley syndrome, an X-linked syndrome with specific thyroid and 
neurological defects, and heart rate abnormalities, thus suggesting a role for MCT8 in TH 
transport in human cardiac tissues. MCT10 has a greater affinity for T3 than T4, and an even 
greater capacity to transport T3 than MCT8 (12). The cardiac myocyte TH-responsive genes 
are expressed as a function of serum T3, and not T4, implying that T4 is neither transported 
across the myocyte sarcolemma nor deiodinated into T3. Therefore, optimal myocyte gene 
expression remains dependent on serum T3 levels, and if they fall, despite the fact that TSH 
and T4 levels may be normal, the heart will express a hypothyroid phenotype. 
TH ACTION ON THE VASCULATURE. TH effects on the vasculature include genomic 
and nongenomic mechanisms that occur at both the vascular smooth muscle and endothelial 
cell levels. Nongenomic, indirect effects of TH include ion channel activation (Na+, K+, Ca2+) 
and regulation of specific signal transduction pathways. Activation of phosphatidylinositol 3-
kinase (PI3K) and serine/threonine protein kinase (AKT) pathways cause the production of 
endothelial nitric oxide, leading to a reduction in systemic vascular resistance through its 
effects on vascular smooth muscle cells (6,13).  Several studies have shown that TH regulates 
endothelial nitric oxide production and vascular tone, and that patients with hypothyroidism 
(both overt and subclinical) and impaired endothelial function show improvement with TH 
replacement therapy (14–16). In addition, T3 can produce a vasodilatory effect within hours 
after administration to patients undergoing coronary artery bypass grafting (17). Similar 
effects are observed when patients with chronic HF are treated with intravenous T3 (18). 
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Thus, T3 has the unique pharmacological properties of an inodilator acting primarily on 
diastolic dysfunction. 
The pulmonary vasculature is not as responsive to the vasodilatory effects TH as is 
the systemic vasculature (19). Pulmonary artery hypertension that resolves after return to the 
euthyroid state has been reported in patients with thyrotoxicosis mainly due to a fall in 
cardiac output. 
THYROID HORMONES AND CARDIOPROTECTION. Cardioprotection is an 
emerging target of therapeutic intervention in AMI to minimize irreversible ischemic damage 
and favor functional recovery of the ischemic-damaged myocardium (20). TH have a role in 
cardioprotection due to activation of cytoprotective mechanisms, stimulation of cell growth, 
neo-angiogenesis, and metabolic adaptation. The net result, as documented by histological 
and functional parameters, is a reduction in myocardial damage and positive reverse left 
ventricular (LV) remodeling, resulting in a delay, or even absence, of evolution toward post-
ischemic irreversible HF. Recent experimental studies using the ischemia/reperfusion rat 
model showed multiple protective effects of TH, particularly on mitochondria. TH is a 
regulator of the tumor suppressor p53, which is activated during AMI, enhancing the 
mitochondrial apoptosis pathway (21). p53 expression, in turn, is blunted by microRNA 30a 
(miR-30a), which is down-regulated in the post-ischemic setting. This favors p53 
accumulation, and therefore enhances mitochondrial dysfunction and bcl-2–like protein 4 
(BAX) activation, resulting in extended myocardial cell loss (22). T3 treatment counteracts 
the decrease in miR-30a levels, thus limiting the activation of p53 and the cascade leading to 
mitochondrial injury and cell death in the AMI border zone (23). This finding is relevant 
because, in patients with post-ischemic HF, p53-responsive microRNA (miR-192, miR-194, 
and miR-34a) levels are elevated in the early phase of AMI and are positively correlated with 
LV diastolic dimension (24). Moreover, T3 mitochondrial protection is also exerted through 
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other pathways, including a mitochondrial adenosine triphosphate–dependent potassium 
pathway, peroxisome proliferator-activated receptor gamma coactivator 1-alpha, and the 
mitochondrial transcription factor A (25). These are key intracellular signals controlling 
mitochondrial activity and biogenesis, and their overexpression limits post-ischemic LV 
remodeling and impairment of cardiac performance. Furthermore, T3 treatment preserves the 
expression of hypoxia-inducible factor 1-alpha, whose protective effect against reperfusion 
injury is mediated by inhibiting the mitochondrial opening of the permeability transition pore 
(26). 
In the context of HF, TH have a cardioprotective role through multifaceted direct or 
indirect actions at the level of the myocytes, the interstitium, and the vasculature (Figure 2) 
(6). TH have an antiapoptotic effect on myocytes via activation of the PI3K/AKT and protein 
kinase C signaling cascades, the expression, phosphorylation, and translocation of heat shock 
proteins 70 (HSP70) and 27 (HSP27), and the suppression of p38 mitogen-activated protein 
kinase signaling (27). In addition, TH treatment reduces interstitial fibrosis in animal models 
of ischemic and nonischemic HF, and this effect can be partially related to the influence of 
TH on the activity of metalloproteinases and their inhibitors (28). Furthermore, the 
antifibrotic effect of TH is also linked to the T3-induced inhibition of profibrotic pathways, 
(29), and is supported by the association of low serum T3 levels with the presence of cardiac 
fibrosis in patients with idiopathic dilated cardiomyopathy (30). 
THYROID DISEASE AND CV RISK FACTORS (Table 2) 
TH AND HYPERLIPIDEMIA. Hyperthyroidism reduces cholesterol levels, which are 
reversed when euthyroidism is achieved. Hypothyroidism is associated with a small, but 
significant increase in lipid parameters (31), in particular, an elevation of low-density 
lipoproteins (LDLs) (32). Hypothyroidism is associated with increased oxidation of LDL, 
which promotes atherogenesis and reverses with treatment (33,34). Lipoprotein(a), a more 
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potent marker of atherogenesis, also increases in overt hypothyroidism and decreases with 
TH replacement (35,36). 
The effect of subclinical hypothyroidism (SCH) on hyperlipidemia is less clear (37–
39). Hyperlipidemia in hypothyroidism is due to a decrease in LDL receptors, resulting in 
reduced cholesterol clearance from the liver and decreased activity of cholesterol 7α-
hydroxylase, which is activated by TH, in breaking down cholesterol (32). A Cochrane 
review of 6 RCTs concluded that levothyroxine treatment of SCH had no overall effect in 
reducing total cholesterol, but suggested a trend toward reducing LDL cholesterol (LDL-C) 
levels >155 mg/dl in a subgroup analysis (40). Two subsequent trials suggested that the 
reduction of LDL-C was approximately 0.3 mmol/l (11.6 mg/dl) (16,41). Thus, an 
association, if present, is likely to be weak, with SCH contributing to a small increase in 
serum LDL-C, ranging between 3 and 15 mg/dl (0.1 to 0.4 mmol/l) (42). This could, in 
theory, contribute to the high risk of CV disease observed in this population. 
TH, VASCULATURE, AND BLOOD PRESSURE. Hyperthyroidism causes a 
hyperdynamic circulation, characterized by increased cardiac contractility and heart rate, 
increased preload, and decreased systemic vascular resistance (SVR), resulting in 
significantly increased cardiac output. Although hyperthyroidism can increase systolic blood 
pressure, the net effect is dependent on the balance between increased cardiac output and 
decreased SVR (43,44). The relationship between subclinical hyperthyroidism (SHyper) and 
blood pressure is less clear, with most published studies showing no association (45–47). 
Furthermore, some studies have shown SHyper patients to have increased carotid intima-
media thickness and carotid artery plaques (48,49), although this was not confirmed in a 
recent large, population-based study (50). 
Overt and subclinical hypothyroidism are associated with diastolic hypertension, 
impaired vascular function, and increased carotid intima hyperplasia (45,47). Endothelial-
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dependent vasodilation is lower in overtly hypothyroid and SCH patients (51), and improves 
with levothyroxine treatment (15,16), as does pulse wave velocity, a surrogate measure of 
arterial stiffness (52,53).  
Several factors could likely contribute to arterial stiffness and endothelial dysfunction 
in SCH and hypothyroidism, including hyperlipidemia and a proinflammatory state (54–56).  
Thus, in the Rotterdam Study, aortic calcification and the prevalence of myocardial infarction 
was higher in patients with SCH who were positive for thyroid autoantibodies than in those 
with SCH alone (57). Both hyperlipidemia and thyroid antibodies are thought to reduce 
expression of endothelial nitric oxide synthase, thereby impairing vasodilation (15). In 
addition, increased arterial stiffness and a low renin state are contributory factors leading to 
blood pressure and vascular dysregulation, due to the lack of the normal vasodilatory effects 
of T3 (4,43).   
TH AND THROMBOGENESIS. Overt and SHyper have been associated with increased 
markers of thrombogenesis (fibrinogen and factor X levels) (58,59). Hyperthyroid patients 
may also have higher von Willebrand antigen levels compared with euthyroid patients, 
leading to enhanced platelet plug formation, which decreases after treatment (60). The 
relevance of these findings is uncertain, although a review of published case reports in 
hyperthyroidism suggests a tendency toward increased overall thrombosis (61). The increased 
cerebral thrombosis and cerebrovascular events in overt hyperthyroidism warrant further 
scrutiny, to investigate if such events are due to increased thrombosis, related to alterations in 
the vascular tree (increased carotid intima-media thickness), or due to a higher risk of atrial 
fibrillation (AF) (49).  
Studies investigating coagulation in overt hypothyroidism have yielded conflicting 
results, with 2 studies demonstrating hypercoagulability (62,63) and 1 study demonstrating 
increased fibrinolysis (64). Interestingly, a study comparing moderate and severely 
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hypothyroid patients with euthyroid controls found that patients with moderate 
hypothyroidism had decreased fibrinolytic activity and were more susceptible to clot 
formation, whereas patients with severe hypothyroidism had increased fibrinolysis and lower 
tissue plasminogen activator antigen (65). In SCH, factor VII activity and the factor VII 
activity to factor VII antigen ratio were significantly increased in women with SCH 
compared with controls (66). Another study demonstrated decreased antithrombin III activity 
and increased levels of fibrinogen, factor VII, and plasminogen activator inhibitor antigen in 
SCH patients to explain a potential hypercoagulable state (67). This is further supported by a 
study that found lower global fibrinolytic activity, such as tissue plasminogen activator, in 
SCH patients than in euthyroid controls (68). The effects of TH on platelet function are 
unclear (60). A study using the Badimon chamber, a surrogate ex vivo model of plaque 
rupture in a moderately stenosed coronary artery, showed increased thrombus in patients with 
SCH 7 to 10 days post–non-ST-segment elevation myocardial infarction compared with 
euthyroid patients, despite dual antiplatelet therapy (69) (Figure 3). This heightened 
thrombogenic state may, in part, explain the higher CV risk seen in patients with SCH. In 
summary, both TH deficiency and excess can alter the coagulation pathway, although the 
precise clinical relevance of this finding is unclear.  
CARDIOVASCULAR CONSEQUENCES OF OVERT AND SUBCLINICAL 
HYPERTHYROIDISM 
Hyperthyroidism is a clinical condition characterized by TH excess, commonly due to 
Graves’ disease, toxic adenoma, and toxic multinodular goiter (70). TH excess increases 
cardiac output by affecting stroke volume and heart rate (6,71). Echocardiographic data 
indicate that short-term hyperthyroidism induces positive CV changes by improving LV 
systolic function and enhancing LV relaxation (diastolic flow velocities and isovolumic 
relaxation time) (72). However, despite the high cardiac output state, hyperthyroid patients 
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have impaired cardiopulmonary function during effort, reflecting their reduced CV and 
respiratory reserve during exercise (70). 
Untreated hyperthyroidism is associated with increased CV morbidity and mortality 
(73). Overt hyperthyroidism has been associated with 16% increased risk of major CV 
events, mainly due to higher incidence of HF events (74). Severe hyperthyroidism may 
induce so-called high-output HF, even in patients without underlying heart disease. This 
congestive circulation results from the increases in blood volume and heart rate, and the 
associated pulmonary arterial hypertension (Figure 4). Clinical features of this condition are 
pleural effusion, hepatic congestion, and fluid retention, which can improve with diuretic 
agents and beta-blockers (75). 
Hyperthyroidism is linked to increased supraventricular ectopic activity (76). The 
onset of AF may increase CV morbidity and mortality, resulting from severe HF and stroke 
(75). T3 increases systolic depolarization and diastolic repolarization, and decreases the 
action potential duration, the refractory period of the atrial myocardium, and the 
atrial/ventricular nodal refractory period. The reduced interatrial action potential duration 
facilitates the occurrence of AF by enhancing the spreading of ectopic activity from the left 
atrium (76). Experimental studies demonstrated that TH excess can provoke the occurrence 
of paroxysmal AF by increasing triggered activity in pulmonary veins (76).  Approximately 
13% of patients with new-onset AF have biochemical evidence of hyperthyroidism, whereas 
AF is noted in 10% to 15% of patients with hyperthyroidism (compared with 0.5% of the 
general population). The main risk factors for the development of AF in hyperthyroid patients 
are increasing age, ischemic heart disease, congestive HF, or heart valve disease (77). The 
risk of ischemic stroke is enhanced by 44% in adults with hyperthyroidism compared with 
euthyroid controls (78). Advanced age and the presence of associated CV risk factors (history 
of HF, hypertension, or diabetes mellitus, previous thromboembolism, left atrial enlargement, 
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and LV dysfunction) can further elevate the embolic risk (70). Despite the evidence of the 
increased rate of stroke, no trials have been performed to assess the risk-benefit ratio of the 
efficacy of anticoagulation treatment in patients with AF and hyperthyroidism. Patients with 
severe hyperthyroidism may have coronary vasospasm leading to chest pain at rest or 
myocardial ischemia (6,70,71,79). Mild and usually asymptomatic pulmonary arterial 
hypertension has been reported, especially in autoimmune hyperthyroidism, with an 
incidence ranging from 36% to 65% in echocardiographic studies (80). 
Prompt recognition and effective treatment of hyperthyroidism is crucial to improve 
the prognosis of hyperthyroid patients (81–83). Antithyroid drugs and beta-blockers represent 
the first-line therapy to control CV involvement of overt hyperthyroidism by restoring 
euthyroidism and controlling the heart rate (82). 
SHyper, affecting up to 1% of the iodine-replete and up to 10% of the iodine-deficient 
adult population, is diagnosed when the serum TSH level is persistently subnormal with 
concomitant free TH levels at the upper limits of their respective reference intervals (4). It 
can be further classified as grade 1 (low, but detectable serum TSH levels [e.g., TSH 0.1 to 
0.39 mU/l]) or grade 2 (suppressed serum TSH levels <0.1 mU/l) (4). Similar to overt 
hyperthyroidism, patients with SHyper may have an increased risk of AF, HF, and CV 
disease. The Thyroid Studies Collaboration, an international consortium, assessed individual 
participant data (IPD) from prospective cohort studies to estimate the risk of HF and CHD 
during median follow-ups of 10.4 and 7 years, respectively (84,85). In age- and sex-adjusted 
analyses, these risks were significantly higher in participants with grade 2 SHyper (HR: 1.94; 
95% CI: 1.01 to 3.72 for HF, HR: 1.21; 95% CI: 0.99 to 1.46 for CHD events, and HR: 1.29; 
95% CI: 1.02 to 1.62 for CHD mortality) than in those with grade 1 SHyper. Moreover, grade 
2 SHyper was associated with a higher risk of developing AF (HR: 2.54 95% CI: 1.08 to 
5.99) than grade 1 SHyper (HR: 1.63 95% CI: 1.10 to 2.41) (85). The attributable risk for AF 
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was 41.5% in these patients, and it was not altered by the presence of existing CV disease or 
other CV risk factors (85). Interestingly, the risk of AF, sudden cardiac death, and reduced 
life expectancy have been noted to be related to higher free T4 levels, even within the 
euthyroid range, in one prospective study of middle-aged and older people from Rotterdam 
(86). Conflicting results have been reported on the association between SHyper and stroke. A 
meta-analysis of 6 studies did not find any evidence supporting an increased risk of stroke in 
participants with SHyper (87). Similarly, a Danish population study did not find any link 
between the risk of stroke and overt, mild, and severe hyperthyroidism after stratifying the 
analysis according to TSH levels (74). 
Management of SHyper should include control of thyroid function and prevention of 
CV complications. International guidelines strongly recommend treatment of grade 2 SHyper 
(TSH <0.1 mIU/l) in patients over 65 years of age and in younger patients with comorbidities 
(81,82). They also recommend treatment of grade 1 SHyper in patients over 65 years of age 
in the presence of CV risk factors or complications, although this recommendation is weak 
because of low-quality evidence (81,82). Treatment of grade 1 SHyper is not recommended 
in young adults. 
CARDIOVASCULAR CONSEQUENCES OF OVERT AND SUBCLINICAL 
HYPOTHYROIDISM 
Overt hypothyroidism is diagnosed when serum TSH is elevated and circulating TH 
are low and is prevalent in 0.2% to 2% of nonpregnant adults (31,37). The causes of 
hypothyroidism are described in Table 3. Overt hypothyroidism has several cardiac 
manifestations, including a reduction in cardiac output, a decrease in heart rate, and an 
increase in peripheral vascular resistance and diastolic dysfunction (71). There are also 
significant changes in modifiable atherosclerotic risk factors, including hypercholesterolemia, 
diastolic hypertension, increased carotid intimal- media thickness, and reduced endothelial 
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nitric oxide, which accompany overt hypothyroidism. All these clinical features are reversible 
with TH replacement (88). 
SCH is diagnosed when serum TH are within their reference range in the presence of 
raised serum TSH concentrations. SCH can be classified as grade 1 (TSH > 4.0 or 4.5, but 
<10 mU/l) or grade 2 (TSH >10 mU/l). In fact, most (at least 80%) patients with 
hypothyroidism have SCH (31). However, there is a lack of consensus on what constitutes 
the “normal” upper limit of TSH leading to controversy on both definition, prevalence and 
clinical significance of SCH (89). The stated prevalence of SCH in published reports ranges 
between 4% to 10% of the adult population, being more common in women and older 
individuals (31,37). This wide range reflects that a variety of factors can influence serum 
TSH levels such as age, sex, body mass index, race, smoking habits, iodine intake, time of 
sampling, concomitant medical conditions and treatments, plus the cutoff concentrations of 
serum TSH used to define the condition. 
The most frequent cardiac abnormality observed in SCH is diastolic dysfunction due 
to impaired ventricular filling and relaxation (90,91). SCH can also impair relaxation of 
vascular smooth muscle cells, inducing increases in systemic vascular resistance and arterial 
stiffness, as well as changes in endothelial function by reduction of nitric oxide availability, 
without apparent clinical significance (92). Population studies support these findings, with 
the Whickham Survey cohort revealing higher systolic and diastolic blood pressures and total 
cholesterol concentrations in SCH individuals than in euthyroid controls (93), and the EPIC-
Norfolk study reporting a worse CV risk factor profile (94). 
There is conflicting evidence from population studies about the association of SCH 
with CV disease and mortality. A number of observational studies of community-dwelling 
individuals have shown an increased risk for CV disease (56,95–97). In addition, SCH after 
admission for an acute cardiac problem has been associated with an up to 3.6-fold increase in 
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cardiac mortality and a 2.3-fold increase in overall death (98). However, this relationship has 
not been confirmed in all studies (94,99,100). This discrepancy in results between the various 
cohorts is likely due to differences in the underlying populations studied and the study 
design. One of the major factors that influence CV risk in SCH populations is age, and 
several observations have concluded that older individuals with SCH may have a lower risk 
of CV disease than younger ones (101). Furthermore, a retrospective observational study 
showed that treatment of SCH with levothyroxine was associated with fewer ischemic heart 
disease events in younger individuals, but this was not evident in older people (102). In 
addition, several studies of older study patients have shown SCH to have either a protective 
or no impact on CV disease risk (103–105). A patient-level meta-analysis of several 
prospective cohort studies, providing 542,494 person-years of follow-up, showed that SCH is 
associated with a higher risk of CV events and mortality in people with higher serum TSH 
levels, particularly in those with TSH levels >10 mU/l, irrespective of age (21). 
Despite the known CV risks associated with SCH, high-quality evidence for treatment 
is lacking, mainly as current data is derived from observational studies or small interventional 
trials with cardiac risk factor changes as outcomes. Trials of levothyroxine in SCH using 
surrogate markers have shown improvement in LV function, vascular endothelial function, 
atherogenic lipid particles, or cardiac mitochondrial function (4,91,105–108). 
RCTs are needed to evaluate the clinical benefits and safety of treatment of SCH in 
reducing CV risk. Meanwhile, international guidelines suggest that treatment should only be 
considered in those with more severe disease (serum TSH > 10 mU/l), symptoms of 
hypothyroidism, or younger than 70 years of age, particularly if they also have other CV risk 
factors (109). 
INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE 
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A few hours after the onset of acute illness, marked changes in serum TH levels 
occur. This is referred to as nonthyroidal illness (NTI). A decrease in T3 and increase in 
reverse T3 (rT3) are the most characteristic and persistent abnormalities of NTI. In severely ill 
patients, T4 levels drop as well. Both low T4 and T3 levels, as well as high rT3 levels are 
associated with a worse prognosis. TSH levels may rise briefly after the onset of disease, but 
despite the drop in serum T3 (and in severe illness also T4) levels, circulating TSH usually 
remains within the low to normal range. Decreased activation and increased inactivation of 
TH are the major causes of these changes in the acute phase of NTI, whereas an altered 
feedback setting at the hypothalamus–pituitary level is more important in the chronic phase 
of severe illness. As low levels of TH are associated with a decreased metabolic rate, the 
changes in TH homeostasis during the acute phase of NTI have been interpreted as an attempt 
to save energy expenditure, which does not require any intervention. However, this remains 
controversial, has been a debate for many years, and may be different in the acute and 
chronic phases of illness (110,111). 
Similar changes occur in patients with CVD. NTI occurs in 15% to 20% of patients 
with AMI (112,113). A rapid but transient decrease in serum TH concentrations occurs 
immediately after AMI (114), with maximal changes between 24 h and 36 h after the onset of 
pain. These changes are due to increased inactivation of TH by the inactivating enzyme 
deiodinase 3 (D3) and decreased activation by D1 and D2 activity (115,116) (Figure 5). 
Although a reduction in oxygen consumption by lowering TH levels during acute ischemia 
could be considered beneficial, the net effect of lower TH levels in the heart may still be 
detrimental because of its important role in post-ischemic LV remodeling, maintaining CV 
function and mitochondrial integrity (6). As in patients with other chronic illnesses, NTI is 
also very common in patients with HF, with a prevalence of about 20% to 30% (117). 
Although these changes may, in part, be due to the illness in general, animal studies provide 
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convincing evidence for additional, specific down-regulation of local TH action in CVD. 
This was first demonstrated in a rat model of right ventricular (RV) hypertrophy and failure, 
where D3 activity increased in the chronically overloaded RV, with no change of activity in 
the LVs of the same hearts (116). D3 activity in the RV of rats with HF was significantly 
higher than that in the RV of rats with hypertrophy alone. Follow-up studies in a post-AMI 
model in mice showed a strong and stable induction of D3 activity in the remodeling 
ventricle from 1 week to at least 8 weeks after AMI (118), and studies in rats have 
demonstrated that the acute decrease in serum T4 and T3 after AMI is mediated by the 
induction of D3 activity in the heart (115). The induction of D3 is localized in 
cardiomyocytes only and is associated with a substantial decrease in tissue T3 concentrations 
and T3-dependent gene expression (118). This change in T3-dependent gene expression was 
independent of the circulating T3 concentration in mice, showing that pathological ventricular 
remodeling after AMI leads to high and stable induction of D3 activity in cardiomyocytes, 
resulting in a subsequent local hypothyroid condition. Whether this local hypothyroidism 
inside the myocardium in patients with HF is beneficial or harmful is unclear. 
Similar to critical illness in general, lower circulating levels of T3 in patients with 
AMI are associated with a more severe clinical condition and with poorer clinical outcome 
(119,120), particularly in patients with LV dysfunction, large AMI, and intense 
proinflammatory and stress responses (121,122). This is not only the case in the acute setting, 
but also in the longer term after recovery from AMI. Low T3 and high rT3 levels at the time 
of AMI are an independent predictor of both short-term and long-term mortality (120), and 
lower T3 levels after AMI are an independent predictor of late recovery of LV function after 
6 months (123). Also, in patients with chronic HF, NTI has been associated with a worse 
prognosis (96,124,125). However, considering the strong effects of disease in general on 
thyroid function, it is impossible to distinguish between cause and consequence in these 
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clinical observational studies. Interestingly, ameliorating oxidative stress with antioxidants 
prevents the acute reduction of serum T3 levels in AMI patients, although it is unknown if 
this has any effect on cardiac function or outcomes (126). 
TH IN AMI AND ISCHEMIA REPERFUSION INJURY  
Low T3 syndrome (an isolated reduction of serum T3 levels with normal T4 and TSH 
concentrations) after AMI is observed in up to 1 in 5 patients (114), whereas SCH is observed 
in almost 12% (127). T3 down-regulation is consistent with experimental data showing that 
changes in circulating TH parameters after AMI are a result of increased D3 activity and 
reduced D1 and D2 activity (115). Convincing data show that TH metabolism abnormalities 
occurring during early stage of AMI are associated with increased incidence of cardiac 
events. The degree of TH down-regulation is associated with higher impairment of cardiac 
function and higher inflammatory response (114,121). 
The increase in rT3, the inactive TH metabolite, is a predictor of both short- and long-
term mortality independent of other traditional parameters (120). Similarly, in 501 patients 
with AMI (of whom 34% had low T3 syndrome), the rate of major cardiac events at follow-
up was higher in those with a low FT3 levels than in those with preserved FT3 circulating 
levels, and, importantly, FT3 was the most important predictor of subsequent cardiac events 
(119). In another study of 457 AMI patients, thyroid dysfunction including SCH, SHyper, 
and low T3 syndrome was associated with higher incidence of major cardiac events (112). 
Furthermore, in patients with AMI and early reperfusion therapy, T3 circulating levels 
correlated with LV ejection fraction both at the early, in-hospital phase and at the 6-month 
follow-up. Interestingly, T3 at 6 months was an independent predictor of LV ejection fraction 
changes between the early and follow-up periods (123). Pathophysiological and therapeutic 
relevance of the thyroid dysregulation after AMI, however, are far from elucidated. No 
interventional studies of TH replacement in AMI patients have been published to date, 
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therefore making a causal relationship between thyroid dysfunction and outcomes difficult to 
ascertain. 
Overall, the experimental and observational findings mentioned previously are in 
contrast to the common interpretation that TH down-regulation after AMI is an adaptive, 
favorable process that helps in reducing catabolism and energy expenditure (128), and 
suggests the potential critical role of the thyroid system in cardioprotection in AMI. Future 
research to better understand the interaction between acute TH changes and cardiac ischemia, 
particularly ischemia-reperfusion injury, and whether normalizing thyroid function 
parameters may have a role, is required. 
TH in HF 
In the clinical setting, the most frequent alteration of TH metabolism is the low T3 
syndrome that occurs in 15% to 30% of HF patients, with the incidence changing in relation 
to the clinical severity of the disease. SCH and SHyper, in contrast, occur in 6% and 3% of 
HF patients respectively (129). Serum T3 levels may be an independent predictor of LV 
dysfunction and New York Heart Association class (130). Furthermore, in addition to 
conventional risk factors, TH metabolism alterations have been associated with a worse 
prognosis in patients with both ischemic and nonischemic LV dysfunction in both acute 
decompensated and chronic stable HF (131–133). In particular, patients with reduced LV 
ejection fraction and low T3 have higher mortality than patients with similar LV ejection 
fractions, but normal T3 (134). This result was also confirmed in a large multicenter cohort of 
patients with ischemic and nonischemic HF with severe LV dysfunction (LV ejection fraction 
≤35%), in which abnormal TH function was associated with significantly increased risk for 
death (135). 
There are a few clinical studies that used disparate methodologies to study the effects 
of TH replacement therapy in HF patients. However, the overall results showed an 
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improvement in CV performance, induced by both direct and indirect actions. Moreover, 
there was also evidence of neuroendocrine system inactivation, resulting from the significant 
reduction in vasoconstrictor/sodium-retaining noradrenaline, aldosterone, and N-terminal 
pro-B-type natriuretic peptide plasma levels (18). These positive results contrast with those of 
another study, which showed that oral T3 treatment is not beneficial in patients with HF and 
moderate LV dysfunction (mean ejection fraction of 43%) (136). Therefore, these discordant 
results suggest that T3 therapy may benefit only a subgroup of patients, and that the dose and 
modality of administration may influence its effectiveness. None of the interventional studies 
of TH in HF patients revealed any major or minor side effects, and it was well-tolerated. In 
contrast, a trial of 3,5-diidrothyropropionic acid (DITPA), a TH analog, was stopped 
prematurely due to the occurrence of thyrotoxic side effects and a trend toward increased 
mortality, suggesting excess DITPA administration (137). These results underscore an 
important endpoint of TH treatment, which is to restore and maintain levels of circulating TH 
and TSH to within their respective reference ranges. Large multicenter trials documenting a 
definite role of TH treatment in HF are lacking. Considering that HF affects millions of 
individuals in the United States, and that TH therapy in a selected group may be safe and 
effective, TH could offer a clinically useful and cost-effective treatment, if confirmed in 
large-scale trials. 
MODULATION OF TH LEVELS BY DRUGS AND ITS IMPACT ON CVS 
AMIODARONE. Amiodarone is a potent class III antiarrhythmic drug that also possesses 
beta-blocking properties. It is an iodinated derivative of benzofuran and is structurally similar 
to TH (Figure 6). Amiodarone contains iodine, and a 200-mg tablet contains 500 times more 
iodine than the average daily requirement (138). Both hyper- and hypothyroidism can occur 
with amiodarone therapy. Amiodarone-induced thyroid dysfunction occurs because of both 
its iodine content and its direct toxic effects on thyroid parenchyma. However, the majority 
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of patients commenced on amiodarone (nearly 90%) remain euthyroid, at least in the short to 
medium term. The prevalence of amiodarone-induced hypothyroidism is between 5% and 
22%, depending on iodine status, being more common in iodine-sufficient regions and in 
those with existing thyroid autoimmunity, and thus is more frequently observed in women. 
The management of amiodarone-induced hypothyroidism is similar to that for all other forms 
of the condition: with levothyroxine replacement. If amiodarone therapy is discontinued, then 
levothyroxine treatment can be stopped after 2 to 4 months in individuals without pre-
existing thyroid autoimmunity. Patients with underlying autoimmune thyroid disease may 
remain hypothyroid, and thus require lifelong levothyroxine treatment, even after amiodarone 
cessation. However, amiodarone-induced thyrotoxicosis (AIT) is seen in 2% to 12% of those 
treated with the drug and is more frequently observed in iodine-deficient areas. AIT is 
categorized into 2 different categories based on the presence of underlying thyroid disease. 
Type 1 AIT occurs in those with pre-existing multinodular goiter or latent Graves’ disease 
and is due to increased synthesis and release of TH. Type 2 AIT, conversely, is observed in 
those without any thyroid abnormalities and is due to destructive thyroiditis, leading to the 
release of preformed TH into the circulation. It is, however, common to have patients with a 
combination of both types of AIT coexisting. AIT can be a difficult condition to diagnose and 
treat. Management of AIT includes cessation of amiodarone, if possible (although its long 
half-life means that the effects could last for months after cessation), with further treatment 
depending on the underlying etiology. Type 1 AIT is usually treated with high doses of 
antithyroid drugs whereas type 2 AIT with corticosteroids. 
PROPRANOLOL. Propranolol decreases circulating serum T3 levels in a dose-dependent 
manner due to inhibition of the deiodinase enzymes (139). This effect is observed in 
hyperthyroid, euthyroid, and levothyroxine-treated hypothyroid patients. Serum free T4  and 
TSH levels remain unchanged. In a clinical context, propranolol is favored over other beta-
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blockers in the management of hyperthyroidism, due to its nonselective -blocking activity 
(to reduce systemic symptoms such as tremor and anxiety), membrane-stabilizing action, and 
reduction in serum T3 levels (20% to 30%, depending on the dose).    
IODINE-CONTAINING CONTRAST DYES USED IN ANGIOGRAPHY. As observed 
with amiodarone, excess amounts of iodine in any form can result in thyroid dysfunction, 
particularly in susceptible individuals. Iodinated contrast media, as used in coronary 
angiograms, contain at least 2,000 times more iodine (depending on the amount of contrast 
used) than the recommended daily allowance in the United States (140). This 
supraphysiological dose of iodine exposure has no major effects on thyroid function in most 
euthyroid individuals but may cause thyroid dysfunction (both hyper- and hypothyroidism) in 
susceptible groups. Data on the prevalence of thyroid dysfunction after coronary angiogram 
contrast exposure is sparse, and no guidelines exist.  However, case-control studies suggest 
that iodinated contrast media exposure at least doubles the risk of subsequent overt 
hyperthyroidism and triples the risk of overt hypothyroidism (141). 
CONCLUSIONS 
The CV system is a major target of TH action, and even subtle changes in thyroid 
function can lead to cardiac dysfunction. A number of experimental studies and observational 
clinical data in both hypo- and hyperthyroidism suggest that modulation of TH may be 
beneficial in reducing CV disease. However, high-quality evidence is required before this can 
be translated into clinical practice. Similarly, there is increasing evidence that changes in TH 
levels in otherwise euthyroid patients with CV disease (such as AMI or HF) may be a marker 
of poor prognosis, and clinical trials are required to see if TH therapy may be efficacious and 
safe. Clinical trials of TH therapy in AMI patients are underway and could provide evidence 
for or against their use in routine clinical care (142,143). These therapies, if proven, could 
provide cost-effective and widely available treatments to millions of patients worldwide.   
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FIGURE LEGENDS 
Central Illustration. The Interactions Between TH and the Cardiovascular System  
Thyroid hormones have a complex relationship with the cardiovascular system through 
multiple mechanisms. The main efects of thyroid hormones are observed on the heart (by 
influencing rate, rhythm, myocardial contraction and risk of coronary artery disease), the 
vascular tree (through regulating blood pressure via smooth muscle tone and endothelial 
function) and by direct effects on cardiovascular risk factors (via lipid metabolism and 
modulation of inflammattory pathways).  
Figure 1. Cellular Pathways and Mechanisms of Action of T3 on the Cardiac Myocyte  
Modified from Klein I, Danzi S (71). AC = adenylyl cyclase; β-AR = β-adrenergic receptor; 
cAMP = cyclic adenosine monophosphate; Ca2+ = calcium ions; Ca2+ ATPase = sarcoplasmic 
reticulum calcium adenosine  triphosphatase; GS = stimulatory G (guanine nucleotide 
binding) protein; K+ = potassium ions; Kv = voltage-gated potassium ion channel; mRNA = 
messenger ribonucleic acid; Na-K ATPase = sodium-potassium adenosine triphosphatase; 
Na+ = sodium ions; NCX = sodium calcium exchanger; PLB = phospholamban; T3 = 
triiodothyronine; TR = thyroid hormone receptor; TRE = thyroid response element. 
T3 has both genomic and nongenomic effects on the cardiac myocyte. Genomic effects are 
mediated by the transport of plasma T3 into the cardiac myocyte and direct binding to thyroid 
hormone receptor (TR), which, in turn, regulate transcription of specific cardiac genes. 
Positively regulated genes are transcribed in the presence of T3, and negatively regulated 
genes are repressed in the presence of T3. Nongenomic mechanisms include direct 
modulation of membrane ion channels.  
 
Figure 2. The role of TH in the Pathophysiology of HF  
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GFR = glomerular filtration rate; HF = heart failure; RAA = renin-angiotensin-aldosterone 
axis; TH = thyroid hormones. 
Figure 3. Thrombus Area Ex Vivo in Representative Patients With Non–ST-Segment 
Elevation Myocardial Infarction by Thyroid Status 
 (Left) SCH (subclinical hypothyroidism) patient. (Right) Euthyroid patient. Reprinted, with 
permission, from Viswanathan et al. (69).  
Figure 4. Mechanistic Effects of Duration of Hyperthyroidism on the Evolution of HF 
AF = atrial fibrillation; CHD = coronary heart disease; HF = heart failure; LVEDV = left 
ventricular end-diastolic volume; LVM = left ventricular mass; SVR = systemic vascular 
resistance. 
Figure 5. Thyroid Function Changes in Critical Nonthyroidal Illness  
(A) The hormonal changes that occur in the hypothalamic–pituitary–thyroid (HPT) axis 
during critical illness. (B) Changes in thyroid hormone entry and metabolism at the level of 
the cardiomyocyte. Direction of arrows ( ) indicate increase (upwards) or decrease 
(downwards), respectively, whereas equal to (=) sign means no change. D (1–3) = deiodinase 
enzymes 1 – 3; rT3 = reverse triiodothyronine; TRH = thyrotropin releasing hormone; TSH = 
thyrotropin; T4 = thyroxine; T2 = diiodothyronine. Other abbreviations as in Figure 1. 
Figure 6. Structural Resemblance of Amiodarone to Thyroid Hormones T4 and T3 
There is a structural similarity between amiodarone and thyroid hormones, with each 
molecule of the drug containing 2 iodine atoms, whereas T4 has 4 and T3 has 3 iodine atoms. 
This structural likeness contributes, in part, to the effects of the drug on thyroid hormones 
and function. Abbreviations as in Figure 5. 
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Table 1. T3-Regulated Cardiac Genes 
Positively Regulated                        Negatively Regulated 
- MHC             -MHC 
voltage-gated K+ channels (Kv1.5, Kv4.2)     Na+/Ca2+ exchanger (NCX1) 
SERCA2         Phospholamban 
Na+/K+ ATPase        Adenylyl cyclase types V, VI 
1-adrenergic receptor       Thyroid hormone receptor 1 
Adenine nucleotide translocase (ANT1)            Thyroid hormone transporters (MCT8, 10) 
Ca2+ = calcium; K+ = potassium; Na+ = sodium; MHC = myosin heavy chain; SERCA 
= sarcoplasmic reticulum adenosine triphosphatase; T3 = triiodothyronine 
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Table 2. Effect of Thyroid Dysfunction on CV Disease Risk Factors 
 Overt Hyperthyroidism 
and Subclinical 
Hyperthyroidism 
Overt Hypothyroidism and 
Subclinical 
Hypothyroidism 
Lipid parameters Mild reduction Increased total cholesterol 
and LDL cholesterol 
Hypertension Systolic hypertension 
Wide pulse pressure 
Diastolic hypertension 
Endothelial dysfunction Excessive endothelial NO 
production and exaggerated 
vascular reactivity 
Increased arterial stiffness 
and carotid intima-media 
thickness in longstanding 
untreated disease 
Impaired endothelial 
dependent vasodilation 
Increased arterial stiffness 
Thrombogenicity Increased fibrinogen and 
vWF in overt disease 
Unclear 
Cardiac function Increased risk of atrial 
arrhythmias 
Increased atrial size, LV 
mass, and impaired diastolic 
function in longstanding 
untreated disease 
LV systolic and diastolic 
dysfunction at rest and 
during exercise 
CV = cardiovascular, LDL = low-density lipoprotein; LV = left ventricular; NO = 
nitric oxide; vWF = von Willebrand factor  
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Table 3. Causes of Hypothyroidism, Including Subclinical Hypothyroidism 
Autoimmune disease Hashimoto’s autoimmune thyroiditis, TSH receptor–blocking 
antibodies 
Structural  Thyroid damage due to thyroidectomy or radiation (radioactive 
iodine therapy or external radiotherapy of head and neck) 
Release of preformed TH Post-thyroiditis state  
Pituitary disease Secondary hypothyroidism due to TSH deficiency 
Drugs Antithyroid drugs, lithium, amiodarone, tyrosine kinase 
inhibitors, interferon therapy, radiographic contrast agents, 
sulfonamides 
Thyroid infiltration Amyloidosis, hemochromatosis, acquired immunodeficiency 
syndrome, sarcoidosis, Riedel’s thyroiditis 
Other Inadequate TH replacement or noncompliance for overt 
hypothyroidism, industrial and environmental agents. 
 
TH = thyroid hormone; TSH = thyrotropin 
 
